ATE363913T1 - Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis - Google Patents

Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis

Info

Publication number: ATE363913T1
Authority: AT; Austria
Prior art keywords: tcf; sepsis; preventives; treat; remedies
Prior art date: 1998-03-19

Application number

AT99909244T

Other languages

English (en)

Inventor

Tohru Tani

Hiroyuki Kondo

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-19

Filing date

1999-03-19

Publication date

2007-06-15

1999-03-19 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

2007-06-15 Application granted granted Critical

2007-06-15 Publication of ATE363913T1 publication Critical patent/ATE363913T1/de

Links

206010028980 Neoplasm Diseases 0.000 abstract 2
206010040047 Sepsis Diseases 0.000 abstract 2
230000003449 preventive effect Effects 0.000 abstract 2
235000021476 total parenteral nutrition Nutrition 0.000 abstract 2
208000035473 Communicable disease Diseases 0.000 abstract 1
208000007746 Immunologic Deficiency Syndromes Diseases 0.000 abstract 1
108010094028 Prothrombin Proteins 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Water Treatment By Sorption (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99909244T 1998-03-19 1999-03-19 Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis ATE363913T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP10070914A JPH11269091A (ja)	1998-03-19	1998-03-19	敗血症予防及び／又は治療剤

Publications (1)

Publication Number	Publication Date
ATE363913T1 true ATE363913T1 (de)	2007-06-15

Family

ID=13445266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99909244T ATE363913T1 (de)	1998-03-19	1999-03-19	Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis

Country Status (13)

Country	Link
US (1)	US20060251615A1 (de)
EP (1)	EP0982037B1 (de)
JP (1)	JPH11269091A (de)
KR (1)	KR100572044B1 (de)
AT (1)	ATE363913T1 (de)
AU (1)	AU753198B2 (de)
CA (1)	CA2288881A1 (de)
DE (1)	DE69936248T2 (de)
DK (1)	DK0982037T3 (de)
ES (1)	ES2288014T3 (de)
TW (1)	TW518229B (de)
WO (1)	WO1999047155A1 (de)
ZA (1)	ZA997352B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4006058B2 (ja)	1997-03-11	2007-11-14	第一三共株式会社	多臓器不全予防及び／又は治療剤
ES2274567T3 (es)	1997-03-14	2007-05-16	Daiichi Pharmaceutical Co., Ltd.	Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ232813A (en) *	1989-03-10	1992-08-26	Snow Brand Milk Products Co Ltd	Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
KR100271087B1 (en) *	1992-07-16	2000-11-01	Snow Brand Milk Products Co Ltd	Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
EP0653211B1 (de) *	1992-07-16	2001-10-17	Snow Brand Milk Products Co., Ltd.	Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil

1998
- 1998-03-19 JP JP10070914A patent/JPH11269091A/ja active Pending
1999
- 1999-03-19 AU AU28536/99A patent/AU753198B2/en not_active Ceased
- 1999-03-19 WO PCT/JP1999/001373 patent/WO1999047155A1/ja not_active Ceased
- 1999-03-19 CA CA002288881A patent/CA2288881A1/en not_active Abandoned
- 1999-03-19 ES ES99909244T patent/ES2288014T3/es not_active Expired - Lifetime
- 1999-03-19 DK DK99909244T patent/DK0982037T3/da active
- 1999-03-19 AT AT99909244T patent/ATE363913T1/de not_active IP Right Cessation
- 1999-03-19 DE DE69936248T patent/DE69936248T2/de not_active Expired - Fee Related
- 1999-03-19 TW TW088104280A patent/TW518229B/zh not_active IP Right Cessation
- 1999-03-19 KR KR1019997010648A patent/KR100572044B1/ko not_active Expired - Fee Related
- 1999-03-19 EP EP99909244A patent/EP0982037B1/de not_active Expired - Lifetime
- 1999-11-26 ZA ZA9907352A patent/ZA997352B/xx unknown
2005
- 2005-07-21 US US11/186,638 patent/US20060251615A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0982037A4 (de)	2004-10-13
ES2288014T3 (es)	2007-12-16
KR100572044B1 (ko)	2006-04-17
AU753198B2 (en)	2002-10-10
EP0982037B1 (de)	2007-06-06
JPH11269091A (ja)	1999-10-05
DK0982037T3 (da)	2007-10-08
EP0982037A1 (de)	2000-03-01
WO1999047155A1 (fr)	1999-09-23
TW518229B (en)	2003-01-21
DE69936248D1 (de)	2007-07-19
CA2288881A1 (en)	1999-09-23
DE69936248T2 (de)	2008-01-31
KR20010012687A (ko)	2001-02-26
US20060251615A1 (en)	2006-11-09
ZA997352B (en)	2000-05-29
AU2853699A (en)	1999-10-11

Similar Documents

Publication	Publication Date	Title
NO20004911D0 (no)	2000-09-29	Antitumormiddel
TR200102020T2 (tr)	2003-01-21	Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler.
EA200600618A1 (ru)	2006-10-27	Применение эффекторов глутаминил- и глутаматциклаз
YU21401A (sh)	2004-03-12	Tetrahidropiridoetri
EP1140840A4 (de)	2002-09-18	-g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
DE59903921D1 (de)	2003-02-06	Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
AP2000001942A0 (en)	2000-12-31	Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
TR200100874T2 (tr)	2001-06-21	Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
DE69839586D1 (de)	2008-07-17	Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung
BG102708A (en)	1999-09-30	4-aminopyrimidine derivatives, medicamentous preparations containing them, their application and method for their preparation
WO1999054326A8 (de)	1999-12-29	Dihydropyrimidine
DK1149910T3 (da)	2004-08-02	Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
ATE386742T1 (de)	2008-03-15	Imidazonaphthyridine
ATE530184T1 (de)	2011-11-15	Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
ATE222119T1 (de)	2002-08-15	Verwendung von erythropoietin zur behandlung von multiple myelom
EA200000240A1 (ru)	2000-10-30	Соединения, препятствующие эффекту раннего превращения лекарственных средств
ATE39357T1 (de)	1989-01-15	Derivate von griseolicsaeure und ihre verwendung.
TR199801732T2 (xx)	1998-12-21	Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
DE59508366D1 (de)	2000-06-21	Verwendung von boswelliasäure zur behandlung von hirntumoren
ATE363913T1 (de)	2007-06-15	Verwendung von tcf-ii zur behandlung oder vorbeugung von sepsis
DE60035133D1 (de)	2007-07-19	Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
DE60226313D1 (de)	2008-06-12	Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
DE3784768D1 (de)	1993-04-22	Verwendung von zusammensetzungen auf basis von crotoxin, zur herstellung von medikamenten zur behandlung von carcinomen.
TR200200987T2 (tr)	2002-09-23	Kanser tedavisine yönelik,ornatılmış pirroller
MXPA01002546A (es)	2004-06-11	Promocion o inibhicion de angiogenesis y cardiovascularizacion.

Legal Events

Date	Code	Title	Description
2009-06-15	EEIH	Change in the person of patent owner
2009-10-15	UEP	Publication of translation of european patent specification	Ref document number: 0982037 Country of ref document: EP
2010-01-15	EEIH	Change in the person of patent owner
2010-12-15	REN	Ceased due to non-payment of the annual fee